Shearman & Sterling advised AcelRx Pharmaceuticals (NASDAQ: ACRX) in its acquisition of Lowell Therapeutics, a company developing Niyad™, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney injury patients in the hospital, which is being studied under an investigational device exemption, and has received Breakthrough Device Designation status from the FDA.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.

The Shearman & Sterling team below included associates Andrew Calamari (New York-Mergers and Acquisitions), Eugene Kim (Washington, D.C.-Tax), Austin Grossfeld (New York-Intellectual Property Transactions) and Naveed Hada (New York-Mergers and Acquisitions).

The Team